Literature DB >> 21217623

Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series.

S Ferlito1, C Liardo, S Puzzo.   

Abstract

AIM: The exact pathogenesis of bisphosphonates-related osteonecrosis of jaws (BRONJ) is still not clear. Two broad theories have been articulated to explain the pathogenesis of BRONJ. One centres on the bisphosphonate induced osteoclast inhibition and the other explains the process in terms of antiangiogenic mechanisms. Both try to address the predilection for this occurrence in the jaws. In most cases the development of osteonecrosis in those taking bisphosphonates (BPs) has been associated with trauma, predominantly dental extraction. This study reports a case series of patients, treated with Zoledronate, submitted to a preventive protocol of dental extraction, in order to minimize the risk of occurrence of bisphosphonates-related osteonecrosis.
METHODS: A total of 34 patients treated with Zoledronate and requiring single or multiple dental extractions were treated, at our Center for research, prevention and care of BRONJ, I Section of Dentistry, Department of Medical Surgical Specialties, University of Catania. The protocol provides an antibiotic prophylaxis and the surgical extraction of interested teeth, accompanied by the removal of the adjacent alveolar bone.
RESULTS: A total of 71 extractions in 34 patients were performed with this approach. The follow-up was 12 months. No signs of inflamed tissue or necrotic exposed bone in any patients.
CONCLUSION: With limits of present study, the results of our case series are very promising because BRONJ did not develop in any of the patients. In all patients taking Zoledronate and showing untreatable inflammatory dental conditions, the present protocol might be advisable.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21217623

Source DB:  PubMed          Journal:  Minerva Stomatol        ISSN: 0026-4970


  6 in total

1.  Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

Authors:  T Hasegawa; S Hayashida; E Kondo; Y Takeda; H Miyamoto; Y Kawaoka; N Ueda; E Iwata; H Nakahara; M Kobayashi; S Soutome; S I Yamada; I Tojyo; Y Kojima; M Umeda; S Fujita; H Kurita; Y Shibuya; T Kirita; T Komori
Journal:  Osteoporos Int       Date:  2018-11-07       Impact factor: 4.507

2.  The Prevention of Medication-related Osteonecrosis of the Jaw.

Authors:  Philipp Poxleitner; Monika Engelhardt; Rainer Schmelzeisen; Pit Voss
Journal:  Dtsch Arztebl Int       Date:  2017-02-03       Impact factor: 5.594

3.  A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Authors:  T Hasegawa; A Kawakita; N Ueda; R Funahara; A Tachibana; M Kobayashi; E Kondou; D Takeda; Y Kojima; S Sato; S Yanamoto; H Komatsubara; M Umeda; T Kirita; H Kurita; Y Shibuya; T Komori
Journal:  Osteoporos Int       Date:  2017-04-27       Impact factor: 4.507

4.  Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk?

Authors:  Peter Johannes Hansen; Michael Knitschke; Florian Guy Draenert; Sebastian Irle; Andreas Neff
Journal:  Clin Oral Investig       Date:  2012-11-01       Impact factor: 3.573

5.  State of oral mucosa as an additional symptom in the course of primary amyloidosis and multiple myeloma disease.

Authors:  Maciej R Czerniuk; Artur Jurczyszyn; Grzegorz Charlinski
Journal:  Case Rep Med       Date:  2014-06-09

Review 6.  The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.

Authors:  Olga Di Fede; Vera Panzarella; Rodolfo Mauceri; Vittorio Fusco; Alberto Bedogni; Lorenzo Lo Muzio; Giuseppina Campisi
Journal:  Biomed Res Int       Date:  2018-09-16       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.